China Biotech In Review: Newsummit To Stage $80 Million IPO On NYSE

 by: ChinaBio Today February 26, 2012 Newsummit Biopharma Holdings, a Shanghai-based CRO offering pre-clinical drug development services, filed to raise up to $80 million in a New York Stock Exchange IPO (see story). The company has offices in five technology parks around China. Newsummit aims to be a one-stop solution for bringing a drug candidate or medical device through an IND (or NDA) filing, after the initial work on the product has been completed. The company uses a network of 99 service providers for most tasks. Pfizer (NYSE: PFE) and Zhejiang Hisun Pharma (SHA: 600267) will put $545 million of assets into their branded generics JV (see story). The investment will consist of off-patent drugs, manufacturing sites and cash. Hisun will contribute $295 million of these assets for a 51% stake in the JV, while Pfizer's portion will be $250 million for the remaining 49%. The two companies signed a MOU to set up the JV in June 2011, and they have now made progress by approving a framework agreement and releasing the financial commitments of each party. Pfizer wants to keep pursuing "opportunities" in China and India to expand its portfolio of generic drugs (see story). The company made the declaration soon after announcing its generic JV deal with Zhejiang Hisun Pharma. According to an unnamed Pfizer spokesperson, Pfizer is open to business development deals of all types, including partnerships, with China and Indian pharmas to help Pfizer attain this goal. Shanghai Fosun Pharma (SHA: 600196), a prolific dealmaker, bought an 18% stake in SD Biosensor, a Korean company that makes in-vitro diagnostic devices. Fosun will become SDB's China distributor as part of the deal. Fosun said SDB's products would add rapid diagnostic tests to its existing portfolio of diagnostic kits. SDB's major revenue-generators are tests for blood sugar and blood lipids. BGI, the China genomics sequencing giant, added another project to its expanding collection of global relationships. The latest collaboration is with Asia Cancer Research Group, a not-for-profit organization comprised of global heavyweights Eli Lilly (NYSE: LLY), Merck (NYSE: MRK) and Pfizer (NYSE: PFE). ACRG is seeking to discover new treatments for Asia's most common cancers. The organization will share its findings with the scientific community to advance treatment of these diseases.

Government and Regulatory As part of the 12th Five-Year Plan, China's ruling State Council will raise the healthcare insurance subsidy for farmers and non-working urban residents by 80%. The increase, which will be put in place by 2015, will take the subsidy up to 360 RMB ($57).

Trials and Approvals  Hutchison MediPharma, the drug discovery company subsidiary of Chi-Med [AIM: HCM], began a first-in-human Phase I clinical trial of a cancer drug, volitinib (HMPL-504), in Australia. Volitinib, the fourth cancer drug that the company has put into clinical trials, is a novel inhibitor of the c-Met receptor tyrosine kinase. In December 2011, Hutchison MediPharma entered a co-licensing agreement for the molecule with AstraZeneca (NYSE: AZN) in a $140 million deal. AstraZeneca assumed responsibility for developing volitinib outside of China. Access Pharma (ACCP.OB) announced that MuGard, its treatment for oral mucositis in cancer patients, received SFDA marketing approval. RHEI Pharma HK Ltd. handled the regulatory process for Access, and Jian An Pharma will market the product in China and Taiwan. Access out-licensed China rights for MuGard to RHEI Pharma in 2008. Dynex Technologies of Virginia received SFDA approval for its DS2R ELISA (enzyme-linked immunosorbent assay) machine. According to Dynex, the DS2 is a smaller, though still automated machine intended for clinics and research institutes with lower levels of demand. The DS2 handles two 96-well microplates and up to 12 different assays per assay run.

Burrill來台成立辦公室 目標中國市場!!

Burrill & Company to open office in Taiwan

2012/02/25  Washington, Feb. 24 (CNA) Burrill & Company, a U.S. life sciences merchant bank that focuses exclusively on companies involved in biotechnology and international medical industries, said Friday it will set up an office in Taiwan as part of a global investment plan. "Taiwan is in a strategically important region that offers tremendous opportunities," said G. Steven Burrill, CEO of Burrill & Company, in a statement. By investing in Taiwan, the company can broaden its access to emerging markets in China and East Asia, the San Francisco-based company said, adding that the office will also offer Taiwanese companies a window on innovation in the West and can help them grow into players on the global stage. Marietta Wu, general manager of Burrill & Company's greater China operations, will serve as manager of the office and will be in charge of investments in Taiwanese firms. Burrill participated in a BioBusiness Asia forum held by the semi-official Industrial Technology Research Institute in 2011 during his last visit to Taiwan. With an eye on the great business potential in the China market, Burrill has suggested that Taiwan take advantage of its relations with China to enter the market. The Council for Economic Planning and Development said last year the company, with US$1.5 billion in assets under management, has agreed to a US$30 million investment in Taiwanese firms.

震波溶脂已核淮; 冷凍溶脂未核淮!!

冷凍溶脂塑身衛署未核淮【2012/02/24聯合晚報】2012.02.2402:55pm日前有醫美診所以「冷凍溶脂」，低溫「凍」死脂肪細胞遭民眾檢舉。衛生署說，目前並沒有核准任何「冷凍溶脂」的醫療器材。報系資料照不動刀的溶脂，瘦鮪魚肚、大腿，讓不少愛美人士心動，但醫師建議，消費者溶脂之前，一定要先檢視問診醫師是有合法執照，更也應確認治療時使用的儀器，是否經衛生署核准，避免發生糾紛，更要小心「溶」出問題。擔心傳統抽脂手術的風險，號稱雕塑曲線的溶脂近來風行，不少醫美診所都推出溶脂療程，除了雷射溶脂以雷射光熱「溶」掉脂肪細胞，日前也有醫美診所以「冷凍溶脂」，低溫「凍」死脂肪細胞，但遭民眾檢舉，衛生署特別出面說明，目前並沒有核准任何「冷凍溶脂」的醫療器材。最近更有醫美診所引進新的震波溶脂，如同超音波震碎體內結石的原理，破壞脂肪細胞。開業醫美診所醫師鄭孝威表示，震波溶脂已獲得衛生署認可，如同體外超音波震碎泌尿道結石的方式，利用特定波長，對皮下1.5公分處破壞脂肪細胞。破壞後的脂肪細胞則會被身體「回收」、代謝，以消掉鮪魚肚，或是能緊實大腿。鄭孝威也說，震波溶脂屬於非侵入性治療，因此比起雷射溶脂，沒有傷口，也較不會造成瘀青，但目前蝴蝶袖及雙下巴等部位仍不適用。對於冷凍溶脂的爭議，鄭孝威建議，消費者除應檢視診所牆面是否有問診醫師的執照，同時也應確認治療時使用的儀器，是否有衛生署核准的適應症與治療用途，避免發生糾紛。

類抽脂術: 聚焦震波技術

標靶震波溶脂掀起非侵入式溶脂風潮[記者謝雨澄台北報導]近年，歐美的醫美體雕市場，已經從傳統侵入式抽脂手術轉為非侵入式整形，成長率高達600%，其中又以「類抽脂術」為發展最快的治療項目—治療時間、恢復期皆短、無傷口、瞄準脂肪細胞作用達長期性效果的種種優點，讓愛美人士趨之若鶩。許多過去以上健身房當作維持身材的時尚都會女性，針對無法靠運動解決的頑固性脂肪區域，都開始選擇接受類抽脂體雕治療--標靶震波溶脂。「標靶震波溶脂儀-UltraShape」是目前全台唯一針對「脂肪細胞膜破壞」的整型外科手術設備。美麗境界診所曾忠仁醫師表示，「標靶震波溶脂儀-UltraShape」，使用非熱能式的聚焦震波技術，以隔山打牛方式將能量集中在皮下1.5公分處的脂肪層作用，精準消滅脂肪且不會對皮膚表層造成熱傷害，進行過程不會傷害任何細胞周圍的神經、血管與結締組織，2周即可看見體圍改變，臨床研究顯示脂肪平均減少在3.5~6.3公分之間，效果可以持續三年，不會有市面上同樣標榜非侵入式身體微整型的其他治療技術所產生的發炎反應、反黑、神經損傷的現象。由於標靶震波溶脂儀-UltraShape是針對脂肪細胞消除，而脂肪細胞有著重量輕體積大的特點，在治療過程後，雖然體重並無顯著的變化，但是身材明顯小一號，特別針對囤積於腰部、腹部與腿部無法單靠運動或減重等方式消除的脂肪細胞進行改善。(2012/2/25)

為何接觸性皮膚炎找上你?

治療接觸性皮膚炎先找刺激因子‧聯合新聞網2012/02/26台北國泰醫院皮膚科主治醫師詹融怡指出，接觸性皮膚炎的成因很多，常見的是戴耳環、項鍊等飾品或手錶，皮膚對鎳、鈷金屬過敏；也有些人擦了首次購買的化妝品或保養品，整張臉都出現過敏反應。台北國泰醫院皮膚科主治醫師詹融怡指出，接觸性皮膚炎的成因很多，常見的是戴耳環、項鍊等飾品或手錶，皮膚對鎳、鈷金屬過敏；也有些人擦了首次購買的化妝品或保養品，整張臉都出現過敏反應。

接觸性皮膚炎外在刺激占8成台北醫學大學附設醫院美容醫學中心主治醫師張宜菁表示，接觸性皮膚炎分兩大類，外來物質的刺激占8成，過敏體質引起的則占其餘2成。外來的刺激物相當多，年輕女性或家庭主婦最常碰到的是化妝品、保養品、項鍊、耳環及清潔劑。拿金屬製的項鍊及耳環來說，大都含有鎳、鈷等金屬，和皮膚接觸久了，引發皮膚炎的機率就相對增加。此外，像陳先生塗敷來路不明的中草藥膏，或是在皮膚傷口上貼了OK繃或膠帶，也常會引起接觸性皮膚炎。另外有些喜歡戶外運動的民眾偶爾也會出現類似狀況，經進一步追查，才知道是不小心接觸到某些有毒植物的樹幹、葉片或汁液，皮膚受到刺激而泛紅發癢。

金屬框鏡架易引發皮膚炎在諸多易引起接觸性皮膚炎的因子中，詹融怡發現，眼鏡是另一個常被忽略的「兇手」。一般說來，金屬框的鏡架比塑膠框鏡架還容易引發接觸性皮膚炎，這是因為鎳、鈷等金屬較易對皮膚造成刺激反應，而不少金屬框鏡架都含有這些金屬成分。針對龐大的近視族群，張宜菁建議選配眼鏡時，不妨選質輕的非金屬鏡框；挑選項鍊及耳環等飾品時，白金、黃金及銀等純金屬材質，又比合金來得好。張宜菁表示，接觸性皮膚炎不見得只出現在和外物接觸的部位，有時也會擴散到其他地方。她就碰過有年輕女孩戴了耳環後，除了耳垂發炎潰爛、濕濕黏黏的，臉頰也冒出一顆顆紅疹子，羞得不敢出門。

新買化妝品先擦手肘試用如何才能避開接觸性皮膚炎？張宜菁建議少碰以前沒用過的化妝品、保養品及金屬飾品。如果真要擦這些化妝品或保養品，也應先小面積擦在手肘內側的皮膚上，觀察皮膚變化，連續擦幾天都沒事後，才可擦到臉上。詹融怡提醒常用這些化妝品、保養品的女性，一但使用後出現皮膚小面積泛紅、發癢或起紅疹，務必盡快就醫，及早找出過敏源，避免過敏症狀反覆發生。